Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Grows By 130.7%

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the recipient of a large growth in short interest in January. As of January 15th, there was short interest totalling 74,300 shares, a growth of 130.7% from the December 31st total of 32,200 shares. Based on an average daily trading volume, of 137,100 shares, the days-to-cover ratio is presently 0.5 days. Approximately 1.4% of the shares of the stock are sold short.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets decreased their target price on shares of Alzamend Neuro from $35.00 to $32.00 and set a “buy” rating on the stock in a research report on Monday, December 16th.

Alzamend Neuro Stock Performance

Shares of NASDAQ ALZN opened at $1.15 on Friday. The firm’s 50-day moving average price is $1.20 and its 200-day moving average price is $1.88. Alzamend Neuro has a 12-month low of $1.06 and a 12-month high of $15.06.

Alzamend Neuro (NASDAQ:ALZN) last issued its quarterly earnings results on Wednesday, December 11th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($2.38) by $1.98. Analysts anticipate that Alzamend Neuro will post -1.68 earnings per share for the current fiscal year.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.